Warfarin-Dose Dx May Not Be Cost-Effective for 'Typical' Patient; May Be for At-Risk Cohort | GenomeWeb

It may not be cost-effective to perform genetic tests to guide initial warfarin dosing in "typical" patients with atrial fibrillation, though it may be cost-effective to test individuals at high risk for hemorrhage, according to a meta-analysis from the University of Cincinnati.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.